Immune cells found near tumours boost breast cancer survival

June 10, 2014

Women with breast cancer are 10 per cent more likely to survive for five years or more if they have certain immune cells near their tumour, according to research published in Annals of Oncology today.

The researchers looked for an immune cell called a killer T cell which specialises in destroying rogue cells in the body, such as .

The Cancer Research UK study found that when these immune cells were present, survival improved for women with ER-negative and ER-positive HER2-postive . However, survival didn't change for women with ER-positive HER2-negative breast cancer.

Study author, Dr Raza Ali, National Institute for Health Research clinical lecturer at the Cancer Research UK Cambridge Institute, University of Cambridge, said: "Cancer often finds ways to escape the , but helping to recognise cancer as a threat - and attack it - provides a promising and powerful avenue for new treatments. We've shown that women who have killer T cells present at the site of their tumour are likely to live longer.

"This important insight could help doctors personalise a woman's treatment based on her immunological profile and also suggests that new treatments should harness the immune system to fight cancer."

Immune cells were counted and analysed from samples collected from 12,439 from four different studies across England and Canada.

The research shows that infiltration into the tumour by killer T cells flags up how certain patients should be treated. The finding also suggests that chemotherapy could be given alongside immunotherapy drugs. Chemotherapy treatment such as doxorubicin in particular may be enhanced when killer T cells are present.

Professor Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, said: "The more we learn about how precisely the immune system interacts with breast cancer the better we are able to fine tune the treatments we give to patients - and the sooner we can save more lives.

"This was the largest ever study of its type looking at data from over 12,000 patients. Crucial research such as this is only possible due to the collaboration available at the Cambridge Cancer Centre, a partnership between Cancer Research UK, the University of Cambridge and Addenbrooke's Hospital."

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "This research highlights the great strides we are making in understanding the complex interplay between cancer and the body's immune system. These studies are key to informing how we are best able to treat in the clinic and to design better drugs that make the best use of the body's own defences."

Explore further: Scientists discover new route to boost pancreatic cancer treatment

More information: Ali HR, Provenzano E, Dawson SJ et al. "Association between CD8+ T-cell infiltration and breast cancer survival in 12439 patients." Ann Oncol 2014. DOI: 10.1093/annonc/mdu191

Related Stories

Scientists discover new route to boost pancreatic cancer treatment

May 30, 2014
Cancer Research UK scientists have uncovered new insights into how a key pancreatic cancer drug – gemcitabine – is broken down in tumour cells, according to research* published in the British Journal of Cancer (BJC), ...

Combining imaging and gene analysis could transform breast cancer diagnosis

October 25, 2012
Combining two approaches - one that digitally scans images of tumour samples and another that analyses genetic information - gives a more accurate prediction of how breast cancer will behave. The research is published today ...

Bacteria may assist the immune system response against cancer

March 3, 2014
(Medical Xpress)—Recent research from the University of Otago shows that bacteria may assist the body's immune system response against cancer cells and help fight tumours like melanoma.

Some immune cells appear to aid cancer cell growth, study finds

September 5, 2013
The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good.

Genetic 'fine tuners' control body's own attack against cancer

May 6, 2013
(Medical Xpress)—The body's own immune system's fight against breast cancer is controlled by genetic 'fine tuners', known as microRNAs, according to a study published in Nature today.

Redirecting our immune cells to help fight children's cancer

November 6, 2013
Immune cells, known as Natural Killer T cells, could be redirected to help fight the childhood cancer, neuroblastoma, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool ...

Recommended for you

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Combining CAR T cells with existing immunotherapies may overcome resistance in glioblastomas

July 19, 2017
Genetically modified "hunter" T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.